|1.||Ilinskaya, Olga N: 1 article (01/2014)|
|2.||Pace, C Nick: 1 article (01/2014)|
|3.||Makarov, Alexander A: 1 article (01/2014)|
|4.||Mitkevich, Vladimir A: 1 article (01/2014)|
|5.||Burnysheva, Ksenia M: 1 article (01/2014)|
|6.||Raines, Ronald T: 1 article (12/2002)|
|7.||Sevcik, Jozef: 1 article (12/2002)|
|8.||Urbanikova, Lubica: 1 article (12/2002)|
|9.||Leland, Peter A: 1 article (12/2002)|
01/01/2014 - "Capacity to induce apoptosis in malignant cells and the absence of necrotic effects make the RNase Sa mutants with high positive charge a suitable anti-cancer agent. "
12/06/2002 - "Like onconase, which is an amphibian ribonuclease in Phase III clinical trials as a cancer chemotherapeutic, RNase Sa3 is not inhibited by the cytosolic ribonuclease inhibitor protein. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2014 - "Using acute myeloid leukemia cells Kasumi-1 we have shown that (i) cytotoxicity of RNase Sa mutants is linearly enhanced by cationization, (ii) the ability of cytotoxic mutants to induce cell death is caused by induction of apoptosis and (iii) localization of positive charge on N-terminus does not contribute to RNase Sa cytotoxicity. "
01/01/2014 - "Cytotoxicity of RNase Sa to the acute myeloid leukemia Kasumi-1 cells depends on the net charge."
|3.||Acute Erythroblastic Leukemia (Erythroleukemia)